Alcon: UBS still buying after quarterly results

(CercleFinance.com) - UBS reaffirms its 'buy' rating on Alcon, as well as its target price of 92 CHF, representing 11% upside potential for the Swiss ophthalmology specialist's shares.


The broker acknowledges a mixed publication for Q2 2024, with adjusted operating profit (core EBIT) missing expectations by 3%, probably due to eye health.

However, in its summary UBS also points out that Alcon's management has reiterated its forecasts, that implantables proved solid and that there was good news concerning dry eye.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.